Staburo is a member of BVMA

Staburo is a member of BVMA

Staburo is a member of BVMA

We haven’t announced it, but since mid of 2023, Staburo is a very proud member of the BVMA (Bundesverband Medizinischer Auftragsinstitute). We are very happy to be one of the 50 member companies and to join this diverse and highly qualified network. We look forward to exciting exchanges, to events and options to share our expertise and to learn from each other.

As an example, which topics are presented at BVMA events, we wrote a short summary about the last symposium:

For the first time as full member, Staburo Head of Quality Dr. Luciana Husfeld and Managing Directors Dr. Josef Höfler and Roland Stieger took part in the BVMA symposium on 24 November 2023, at the Holiday Inn City Centre Hotel in Munich. This year it was the 31. BVMA symposium and the get-together took place the evening before at the venue.

This year’s topic was: “Rethinking clinical research: From patients to AI”. The symposium presentations and discussions covered the areas of regulatory, experiences with CTR/CTIS and as well patient participation and AI applications within clinical research.

We were very happy to learn more about current changes in regulations and updates in the CRO market – thank you for the excellent networking sessions! Congratulations to the BVMA for the organization of this great event and thank you for the invitation! We are already looking forward to next BVMA symposium on 22nd of November 2024.

The BVMA represents the interests of its German CRO members. BVMA members maintain a lively exchange of information on topics that important to the German CRO industry, e.g. on questions of liability and insurance, education and training, quality requirements and trends in the pharmaceutical and CRO industry.

Data analysis, clinical biostatistics and more.

Health @ Staburo

Health @ Staburo

Health @ Staburo

The topic health is one of the most important of Staburo with our core purpose to deliver excellent data science to improve and save lives. In addition, this is also a very important concern for our company and our team members. A great work environment is key for us at Staburo – this also includes physical and mental health conditions of our employees.

In line with that our Managing Director, Josef Höfler, successfully completed the training program: Healthy Leadership – Strengthen leadership and mental health at TUM Institute for LifeLong Learning in autumn 2023.

Target group for this training program is as follows: Managers, Executives, HR managers, or anyone interested in the topic of mental health at work. The comprehensive program consists of contents such as evidence-based and field-tested methods, realistic role plays, online learning elements, personal video feedback, and coaching.

Over a total of 6 days, the following topics were dealt with, deepened, and discussed:

  • Introduction to mental health
  • Employee appraisal with mental health focus
  • (Self-) management
  • Special case of burnout and risk assessment

Josef Höfler stated: “The training program on Healthy Leadership provided me with valuable insights and practical tools to support our team members and create a positive work environment. We are committed to continuously integrating these learnings into our company culture and practices.”

Beyond that, an anonymous survey on (mental) well-being and health including a risk assessment was conducted at Staburo in summer 2023. The average results were in our eyes very good, nevertheless there are always areas with room for improvement and things we would like to address more to support a healthy work environment for all of us at Staburo.

To give this topic more weight internally, the first Staburo health day took place in October 2023. The presentations and activities during this day focused on topics such as: Stress reduction, ergonomics at work, eye check-ups, active breaks, and nutritional aspects. It was a successful kick-off, but of course the topic of (mental) health of our employees is not completed and will be continuously on our agenda.

Data analysis, clinical biostatistics and more.

Staburo is top company 2024

Staburo is top company 2024

Staburo is one of the top companies 2024

We are proud to announce that the employer rating platform kununu recognizes Staburo GmbH as top company 2024.

The award is based on the independent assessments of our employees on the platform. This makes Staburo one of the companies with the best working environment in Germany.

This result is in line with our company philosophy. We are committed to the highest ethical standards, social responsibility, and integrity. We have a common mindset which reflects current social topics including compliance, data privacy, environmental sustainability, protection of human rights, gender diversity, fairness, and ethical behaviour.

Staburo’s Managing Directors – Hannes Buchner, Josef Höfler and Roland Stieger – emphasize that a great work environment is key in our company. The character of our company culture and spirit is based on our core values: permanence, open-minded, service and support mindset, solidarity and fun, curiosity and willingness to learn, reliability and commitment. Our daily communication and interactions within the team, towards clients and partners are built on these fundamental principles.

We are delighted about this award with 4.7 out of 5 stars and would like to thank all our employees for their continuous great work, trust and feedback.

Click here for our kununu company profile: https://www.kununu.com/de/staburo1

We look forward to continuing to deliver excellent data science to improve and save lives.

Happy new year 2024 to everyone!

Data analysis, clinical biostatistics and more.

Staburo Christmas Party 2023 & Merry Christmas

Staburo Christmas Party 2023 & Merry Christmas

Staburo Christmas Party 2023 & Merry Christmas everyone

A couple of days ago we came together in Munich for our annual Christmas party. All colleagues from Munich, the surrounding area or even from other cities met at Nockherberg for our first Staburo ice curling company event. Our colleagues played across teams enthusiastic and fully committed on four lanes, drank mulled wine, and enjoyed the winter wonderland.

Followed by this fun and snowy part of ice curling we all moved on together to our dinner location – Falke 23 in Munich. Here we spent a wonderful evening with delicious food, good drinks, an award ceremony, as well as many conversations and laughts. We are delighted with this successful evening and that so many of our colleagues were able to attend!

Once again, we would like to thank all our employees for their great commitment and our customers for their trust and great cooperation. We are already looking forward to the next year and what it has to offer for all of us.

We wish you a merry Christmas, relaxing holidays, and a happy new year 2024!

Data analysis, clinical biostatistics and more.

Staburo presents @ PSI Biomarkers SIG meeting

Staburo presents @ PSI Biomarkers SIG meeting

Staburo presents @ PSI Biomarkers SIG meeting

A couple of weeks ago, Staburo’s Head of Biostatistics and Managing Director, Hannes Buchner, took the opportunity to share insights from the research project titled “Deriving Interpretable Thresholds for Variable Importance in Random Forests by Permutation” at the monthly meeting of the PSI Biomarkers European Special Interest Group (SIG). 

PSI, a non-profit community, is committed to advancing and promoting the use of statistics within the healthcare industry to ultimately benefit patients. Connecting over a thousand members and fostering communication among more than 2000 individuals in its online communities, PSI offers a platform where professionals can exchange ideas and network. Throughout their careers, members are supported with resources such as scientific meetings, online training, networking events, and the journal Pharmaceutical Statistics. 

The PSI Biomarkers SIG, comprising 44 members from industry and academia, aims to develop advanced analytical methods for biomarker analysis in clinical development. The group also seeks to enhance interaction with various disciplines and establish connections with other SIGs. 

Hannes’ presentation detailed a collaborative effort between Staburo employees Laura Schlieker, Maria Blanco and Tim Müller, Armin Ott from Roche Diagnostics and Roman Hornung from the Institute for Medical Information Processing, Biometry and Epidemiology, University of Munich. The project explores the Random Forest (RF) method and its application in high-dimensional data analysis, biomarkers research, and personalized medicine. The research group has been focused on identifying all relevant covariables in RF predictions. During the presentation, Hannes introduced the Boruta algorithm, outlined the improvements proposed by the research group, and compared the performance of both methods using real and simulated data sets. 

Staburo’s participation in the PSI Biomarkers SIG meeting was an opportunity to engage with its members – thanks for the great organisation!

Data analysis, clinical biostatistics and more.

Staburo @ APF meeting 2023

Staburo @ APF meeting 2023

Staburo @ APF meeting in Darmstadt

A few days ago – we from Staburo GmbH, Hannes Buchner, Stephan Bischofberger, Gabriele Bleckert, Sarah Musiol, Jiali Lin  – joined the annual APF meeting in November: It all started with a fantastic get-together on Thursday evening at the Grohe Brauhaus in Darmstadt. We had a great evening and lots of networking opportunities in this location with joining so many participants from our industry.

The next day started with our morning session including 4 great and interesting presentations about biomarkers and decision making of which one was by our Managing Director, Hannes Buchner. We gained many insights into biomarker analyses and tools at different companies from sponsors to CROs.

After a well-deserved lunch break we kicked-off our afternoon session which was about estimands in early phase trials in oncology with 2 presentations. During those sessions and discussions the topic how to use estimands in early phase was challenged and in the end still recommended to use at least an ‘estimand thinking’ approach, since it is a must in late phase trials and since it helps understanding the actual objectives of the whole development program.

Many thanks to Merck for organizing and hosting this year’s meeting and also to everyone who joined and contributed to this interesting and insightful event.

We are already looking forward to the next meetings!

Data analysis, clinical biostatistics and more.